| Code | CSB-RA011661MB7HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to QX-005N, targeting the interleukin-4 receptor (IL4R), a critical component in type 2 immune responses. IL4R exists as a heterodimeric receptor complex that binds both IL-4 and IL-13, two key cytokines that drive allergic inflammation, IgE production, and alternative macrophage activation. Upon ligand binding, IL4R initiates JAK-STAT6 signaling cascades that promote Th2 cell differentiation and contribute to the pathogenesis of atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis. Dysregulated IL4R signaling is also implicated in fibrotic diseases and certain malignancies where type 2 inflammation plays a role.
QX-005N represents a research-grade reference antibody designed to block IL-4 and IL-13 signaling through IL4R inhibition. This biosimilar provides researchers with a valuable tool for investigating type 2 inflammatory mechanisms, evaluating therapeutic intervention strategies, and studying IL4R-mediated cellular responses in various disease models. It supports immunological research, drug development studies, and mechanistic investigations of allergic and inflammatory conditions.
There are currently no reviews for this product.